Is there a need to review the syndromic case management of vaginal discharge due to candida in the Indian scenario?

Swati T. Gedam; Manjushri M. Waikar; Kalindi S. Deogade; Manisha K. Sharma; Sonali S. Gosavi; Vandana A. Agarwal

doi:10.18203/2320-6012.ijrms20232416

Authors

Swati T. Gedam Department of Microbiology, Government Medical College Nagpur, Maharashtra, India
Manjushri M. Waikar Department of Obstetrics and Gynecology, Government Medical College Nagpur, Maharashtra, India
Kalindi S. Deogade Department of Microbiology, Government Medical College Nagpur, Maharashtra, India
Manisha K. Sharma Department of Microbiology, Government Medical College Nagpur, Maharashtra, India
Sonali S. Gosavi Department of Microbiology, Government Medical College Nagpur, Maharashtra, India
Vandana A. Agarwal Department of Microbiology, Government Medical College Nagpur, Maharashtra, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20232416

Keywords:

Fluconazole, Kit-2, Resistance, RPMI 1640, Vulvovaginal candidiasis

Abstract

Background: Vulvovaginal candidiasis (VVC) affects approximately 75% of women once in lifetime. National AIDS Control Organization has recommended Kit-2/Green (tablet secnidazole 2 gm OD stat and capsule fluconazole 150 mg OD stat) for syndromic case management (SCM) of patients with vaginal discharge since 2007. Patients are frequently revisiting the STI centre with recurrent VVC. The purpose of the study was to determine the effectiveness of fluconazole and other azoles in vulvovaginitis.

Methods: Vaginal swabs from 188 patients attending regional STI centre, at Government Medical College, Nagpur between October 2020 to June 2022 were processed. A total of 128 conventionally confirmed isolates of Candida species were tested on RPMI 1640 medium for susceptibility to azoles by E test. An MIC of ≥8 μg/ml for fluconazole and ≥1 μg/ml for itraconazole, ketoconazole and voriconazole was interpreted as resistance as per CLSI M-60.

Results: Candida species isolated were Candida albicans, C. glabrata, C. tropicalis, C. parapsilosis, C. dubliniensis and C. krusei. Candida species resistant to fluconazole, itraconazole, ketoconazole and voriconazole were 22 (17.18%), 53 (41.40%), 19 (14.84%), and 3 (2.34%) respectively. C. glabrata was most resistant while C. parapsilosis was least resistant. Voriconazole was most effective.

Conclusions: Extensive use of fluconazole in syndromic case management of vaginal discharge could be the probable reason for 17.18% resistance to fluconazole. Withdrawal of fluconazole and replacement with another antifungal azole in SCM of vaginal discharge may prevent recurrent VVC and perhaps lead to emergence of fluconazole sensitive candida.

Metrics

Metrics Loading ...

References

Simplified STD Treatment Guidelines, Consultation with Technical Experts. Nation AIDS Control Organization, Ministry of Health and Family Welfare. Government of India: New Delhi; 1993.

National Guidelines on Prevention, Management and Control of Reproductive Tract Infections Including Sexually Transmitted Infections. National AIDS Control Organization. Department of AIDS Control, Ministry of Health and Family Welfare. Government of India: New Delhi; 2007.

Ahmad A, Khan AU. Prevalence of Candida species and potential risk factors for vulvovaginal candidiasis in Aligarh, India. Eur J Obstet Gynecol Reprod Biol. 2009;144:68 71.

Olowe OA, Makanjuola OB, Olowe R, Adekanle DA. Prevalence of vulvovaginal candidiasis, trichomoniasis and bacterial vaginosis among pregnant women receiving antenatal care in Southwestern Nigeria. Eur J Microbiol Immunol. 2014;4:193 7.

Chander J. Candidiasis. In: A textbook of Medical Mycology. 3rd edn. Mehta Publishers: New Delhi; 2009:266-290.

Chander J. Candidiasis. In: A textbook of Medical Mycology. 4th edn. Mehta Publishers: New Delhi; 2018:401-423.

Zarrinfar H, Kord Z, Fata A. High incidence of azole resistance among candida albicans and C. glabrata isolates in Northeastern Iran. Curr Med Mycol. 2021;7(3):18-21.

Wang FJ, Zhang D, Liu ZH, Wu WX, Bai HH, Dong HY. Species distribution and in vitro antifungal susceptibility of vulvovaginal Candida isolates in China. Chinese Med J. 2016;129(10):1161-5.

Standard Operative Procedures for Fungal Identification and Detection of Antifungal Resistance. 2nd Edition. Indian Council of Medical Research New Delhi: India; 2019.

CLSI. Performance standards for susceptibility testing of yeasts. Approved guidelines. 2nd edn. CLSI supplement M- 60. Wayne, PA: Clinical and Laboratory Standards Institute; 2020.

de Cássia Orlandi Sardi J, Silva DR, Anibal PC, de Campos Baldin JJ, Ramalho SR, Rosalen PL, et al. Vulvovaginal candidiasis: epidemiology and risk factors, pathogenesis, resistance, and new therapeutic options. Curr Fung Infect Rep. 2021;15:32-40.

Chaudhary P, Singla A, Mamoria VP, Mittal S, Bacchani D. Prevalence of non-albicans candida and its antifungal susceptibility at a tertiary care hospital, Jaipur. Int J Contemp Med Res. 2020;7(7):1-5.

Kumar S, Goyal R, Kumar A. Determination of Vulvovaginal Candidiasis in Tertiary Care Hospital. Asian J Pharma and Clin Res. 2022;15(8):201-4.

Mukasa KJ, Herbert I, Daniel A, Serunkuma KL, Joel B, Frederick B. Antifungal susceptibility patterns of vulvovaginal candida species among women attending antenatal clinic at Mbarara Regional Referral Hospital, South Western Uganda. HHS Public Access. 2015;5(4):322-31.

Khan M, Ahmed J, Gul A, Ikram A, Lalani FK. Antifungal susceptibility testing of vulvovaginal Candida species among women attending antenatal clinic in tertiary care hospitals of Peshawar. Infect Drug Resist. 2018;11:447-56.

Kombade S, Abhishek K, Mittal P, Sharma C, Singh P, Nag V. Antifungal profile of vulvovaginal candidiasis in sexually active females from tertiary care hospital of western Rajasthan. J Fam Med Prim Care. 2021;10:398-02.

Shi XY, Yang YP, Zhang Y, Li W, Wang JD, Huang WM, et al. Molecular Identification and Antifungal Susceptibility of 186 Candida Isolates from Vulvovaginal Candidiasis in Southern China. J Med Microbiol. 2015;64:390-3.

Das KH, Mangayarkarasi V, Sen M. Antifungal resistant in non-albicans candida species are emerging as a threat to antenatal women with vulvovaginal candidiasis. Biomed Pharmacol J. 2019;12(3):1369-78.

FDA Drug Safety Communication. FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems. 2013.

El-Feky DS, Gohar NM, El-Seidi EA, Ezzat MM, AboElew SH. Species identification and antifungal susceptibility pattern of Candida isolates in cases of vulvovaginal candidiasis. Alex J Med. 2016;52:269-77.

Salehei Z, Seifi Z, Zarei Mahmoudabadi. A sensitivity of vaginal isolates of candida to eight antifungal drugs isolated from Ahvaz, Iran. Jundishapur J Microbiol. 2012;5(4):574-7.

Milici ME, Maida CM, Spreghini E, Ravazzolo B, Oliveri S, Scalise G, et al. Comparison between disk diffusion and microdilution methods for determining susceptibility of clinical fungal isolates to Caspofungin. J Clin Microbiol. 2007;45:3529-33.

Matar MJ, Ostrosky-Zeichner L, Paetznick VL, Rodriguez JR, Chen E, Rex JH. Correlation between E-test, disk diffusion, and microdilution methods for antifungal susceptibility testing of fluconazole and voriconazole. Antimicrob. Agents Chemother. 2003;47:1647-51.